Profound Medical Corp
$ 7.38
1.79%
31 Jul - close price
- Market Cap 268,172,000 USD
- Current Price $ 7.38
- High / Low $ 7.44 / 7.09
- Stock P/E N/A
- Book Value 1.64
- EPS -1.24
- Next Earning Report 2026-08-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.36 %
- ROE -0.71 %
- 52 Week High 8.95
- 52 Week Low 3.76
About
Profound Medical Corp. The company is headquartered in Mississauga, Canada.
Analyst Target Price
$11.14
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-03-05 | 2025-11-13 | 2025-08-14 | 2025-05-08 | 2025-03-06 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-03-07 | 2023-11-02 | 2023-08-09 |
| Reported EPS | -0.19 | -0.27 | -0.26 | -0.52 | -0.36 | -0.2 | -0.38 | -0.28 | -0.26 | -0.42 | -0.26 | -0.35 |
| Estimated EPS | -0.25 | -0.302 | -0.38 | -0.4 | -0.28 | -0.3225 | -0.3 | -0.28 | -0.31 | -0.32 | -0.32 | -0.34 |
| Surprise | 0.06 | 0.032 | 0.12 | -0.12 | -0.08 | 0.1225 | -0.08 | 0 | 0.05 | -0.1 | 0.06 | -0.01 |
| Surprise Percentage | 24% | 10.596% | 31.5789% | -30% | -28.5714% | 37.9845% | -26.6667% | 0% | 16.129% | -31.25% | 18.75% | -2.9412% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.22 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PROF
2026-07-30 10:40:56
Profound Medical Corp (PROF) currently holds a financial score of 6.62, placing it 145th out of 199 companies in the Healthcare Equipment & Supplies industry. The company exhibits robust financial health but low operating efficiency. Its latest quarterly revenue increased by 103.62% year-over-year to $5.34 million, accompanied by a 34.23% year-over-year rise in net profit.
2026-07-30 02:40:56
This article provides an "Institutional Confidence" score for Profound Medical Corp (PROF), showing it has maintained a score of 3.00 as of July 29, 2026. It details changes in shareholdings by various institutional investors, including Fidelity Investments Canada ULC, Gagnon Securities LLC, Royce Investment Partners, Rosalind Advisors, Inc., and Timelo Investment Management Inc., highlighting significant increases in shares held by several. The report indicates a positive trend in institutional interest, with most major holders increasing their positions.
2026-07-29 03:09:45
Profound Medical Corp (PROF) displays strong fundamentals and high growth potential, with its revenue averaging 123.61% year-on-year over the past three years. The stock is considered fairly valued and has high institutional ownership. Analysts rate it as a "Strong Buy" with a target price of $11.05, suggesting a 50.75% upside.
2026-07-28 02:41:14
This article provides a risk assessment for Profound Medical Corp (PROF), detailing its current risk score, beta value, and various volatility and drawdown metrics. The company's risk assessment score is 3.00, placing it 129 out of 199 in the Healthcare Equipment & Supplies industry. Key financial indicators such as VaR, maximum drawdown, and Sharpe Ratio over different periods are also presented.
2026-07-28 02:40:38
Profound Medical Corp (PROF) shows healthy fundamentals and significant growth potential, although its valuation is considered fairly valued within the Healthcare Equipment & Supplies industry. Institutional ownership is high, and analysts largely rate it as a Buy with a target price of 11.05. Despite good market performance and outperforming fundamentals, technical indicators suggest the stock is trading sideways, suitable for range-bound swing trading.
2026-07-28 01:53:00
Raymond James upgraded Profound Medical Corp. (NASDAQ:PROF) to Strong Buy from Outperform, maintaining an $11.00 price target, following positive data from the company's CAPTAIN trial and favorable reimbursement developments for its TULSA procedure. The TULSA procedure showed no median change in penile length for patients one month post-treatment, contrasting with a reduction in those undergoing robotic radical prostatectomy. Additionally, the company experienced a 59% revenue surge and 71% gross profit margin over the last year.
